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Objectives: Assess the relative clinical and economic value of Ipilimumab as 
second-line treatment of metastatic melanoma compared with other metastatic 
cancers agents in Brazil. MethOds: A literature review of clinical data supporting 
approval of various metastatic cancers agents meeting the following criteria: market 
and price approval in Brazil within the last 10 years, OS as primary/secondary end-
points in clinical trials, median OS at time of regulatory approval and availability of 
Kaplan-Meier OS curves, was conducted. The studies selected provided data to ana-
lyze changes in median/mean OS, on 1-year survival rate in absolute (i.e. months) 
and relative (i.e. percent of improvement) terms and NNT at 1 year to avoid one 
death. Clinical outcomes were associated with drug costs, which were obtained from 
the official Brazilian price list issued on 20/Jan/2015 by CMED. Results: Relative to 
other agents, ipilimumab demonstrated absolute improvement in mean OS of 6.1 
months (versus 0.1-6.4 months), a relative improvement in mean OS of 53% (versus 
1.3-34.3%), absolute improvement in median OS of 3.7 months versus 0-13.3 months 
(76,92% were ≤ 4 months with other agents), relative improvement in median OS 
of 57.8% (vs 0-63.3%), absolute improvement in 1-year survival rate (20.3% versus 
0-15.0%), relative improvement in 1-year survival rate (80.2% versus 4.2-81.5%) and 
the lowest NNT at 1 year to avoid 1 death (5 patients versus 6.47–31.5 patients). 
Ipilimumab’s relative value was confirmed when plotting each drug’s clinical per-
formance vs total drug costs. cOnclusiOns: Results document that second-line 
ipilimumab demonstrates relative median OS and absolute mean OS improvements. 
Ipilimumab achieved the greatest relative mean OS improvement, absolute 1-year 
survival rate improvement and the lowest NNT at 1 year. Comparative analysis 
demonstrates the clinical and economic value of Ipilumumab. This analysis pro-
vides health-care decision makers another tool in their decision making process.
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ObjectivOs: Estimar los costos del Cáncer de Mama (CMA) en los establecimien-
tos del Ministerio de Salud del Perú. MetOdOlOgíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes con CMA afiliados al Seguro Público de Salud 
(Seguro Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva 
del financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratamiento y 
seguimiento de la enfermedad) provienen de las Condiciones Asegurables del Plan 
Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo clínico se 
ha estimado con la metodología de costeo estándar. El costo total fue ajustado por 
factores de oferta, demanda y adherencia. ResultAdOs: La cohorte hipotética de 
CMA es de 658 personas para el año 2014 (Incidencia de CMA temprano en Perú: 
29 x 100,000 y de CMA localmente avanzado: 13 x 100,000). El costo total para CMA 
es de 36,245,142 dólares correspondiendo a CMA temprano: 29,642,129 dólares y 
para CMA localmente avanzado: 6,603,013 dólares. El costo total correspondiente a 
prevención es de 24,068 dólares (0.1%), diagnóstico 109,706 dólares (0.3%), tratami-
ento 36,032,944 dólares (99.4%) y para seguimiento 78,424 dólares (0.2%). El costo 
fijo correspondió a 6,838,797 dólares (18.9%) y el costo variable a 29,406,345 dólares 
(81.1%). cOnclusiOnes: El costo anual total para Cáncer de Mama en el Perú se 
estimó en 36,245,142 dólares. Este monto representa el 19.6% del presupuesto anual 
en el programa presupuestal de prevención y control del cáncer del país.
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ObjectivOs: Estimar los costos del Cáncer de Próstata (CP) en los establecimien-
tos del Ministerio de Salud del Perú. MetOdOlOgíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes con CP afiliados al Seguro Público de Salud 
(Seguro Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva 
del financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratamiento y 
seguimiento de la enfermedad) provienen de las Condiciones Asegurables del Plan 
Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo clínico se 
ha estimado con la metodología de costeo estándar. El costo total fue ajustado por 
factores de oferta, demanda y adherencia. ResultAdOs: La cohorte hipotética de 
CP es de 1,167 personas para el año 2014 (Incidencia de CP: 51 x 100,000). El costo 
total para CP es de 4,902,659 dólares correspondiendo a CP Estadio I: 437,084 dólares, 
CP Estadio II: 4,051,303 dólares y Estadio III: 414,273. El costo total correspondiente 
a diagnóstico es de 296,583 dólares (6.0%), tratamiento 4,536,335 dólares (92.5%) y 
para seguimiento 69,742 dólares (1.4%). El costo fijo correspondió a 4,140,073 dólares 
(84.4%) y el costo variable a 762,587 dólares (15.6%). cOnclusiOnes: El costo anual 
total para Cáncer de Próstata en el Perú se estimó en 4,902,659 dólares. Este monto 
representa el 2.6% del presupuesto anual en el programa presupuestal de prevención 
y control del cáncer del país.
Objectives: To determine the cost-effectiveness of Ben-R versus R-CHOP for the 
first-line treatment of patients with iNHL in Colombia. MethOds: An economic 
model was constructed from the Colombian public payer perspective, with a life-
time horizon and discount rate of 5%. The model included three health states: 
progression-free (PF), progressive disease (PD) and death. Clinical inputs and PFS 
information were based on phase 3 clinical data. Overall survival (OS) data was 
not mature at the time of publication and the model conservatively assumes 
non-differential survival, estimated by disease-related mortality adjustments 
applied to all-cause mortality rates in Colombia. Therefore, the analysis focused 
on progression-free life year (PFLY) outcomes as the most relevant measure of 
incremental treatment effect. Treatment patterns for 1st and 2ndline chemo-
therapy and resource use for disease monitoring and adverse event manage-
ment were based on the expert input of a Colombian hematologist. Unit costs 
(reported in 2014 Colombian Pesos) were estimated via EPS manager interviews 
and SISMED published rates. Results: The total lifetime cost per iNHL patient 
was $292,962,824 for Ben-R and $249,522,769 for R-CHOP. Total life years were 
7.80 for both arms but Ben-R demonstrated gains in QALYs (5.86 vs. 5.49) and 
PFLYs (5.58 vs. 3.62) over R-CHOP given improvements in PFS. The ICER per PFLY 
of $22,091,813 demonstrates that the use of Ben-R is cost effective, as the ICER 
falls below the willingness to pay (WTP) of Colombia at three times the GDP per 
capita ($44,788,404). Univariate sensitivity analysis revealed that the ICER per 
PFLY was most sensitive to the hazard ratio for PFS, number of Ben-R treatment 
cycles and the discount rate for outcomes. Probabilistic sensitivity analysis esti-
mated that Ben-R had an 88% chance of being cost-effective based on current WTP 
thresholds. cOnclusiOns: Ben-R is a cost-effective alternative to R-CHOP for the 
first-line treatment of iNHL in Colombia.
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Objectives: To calculate the distribution among treatment related average costs 
of the use of TKI’s versus the combination of pemetrexed/cisplatin in relation to 
four core cost items: Acquisition, application, medical care and disease progres-
sion. MethOds: A discrete event simulation cost-effectiveness model with one 
month cycles (progression free, disease progression and death) assessed treatment 
related costs in a five year horizon until death. Average costs for TKIs where taken 
from three different therapies: afatinib, erlotinib and gefitinib. Public institutional 
direct medical costs (2014 purchases and price tabulators) were retrieved to adopt 
the national health system perspective. Efficacy inputs where obtained from a net-
work meta-analysis. Information gaps related to the use and frequency of medical 
resources where fulfilled with the results of a Delphi panel (10 oncologists of all 
major public institutions). The distribution among core cost items was calculated 
and later compared to obtain its share from the total treatment cost. Results: In 
the studied time horizon, the highest cost of treatment was reported by pemetrexed/
cisplatin with US$175,563, followed by a TKI mean of US$124,005. Disease progres-
sion cost was the most expensive item among alternatives, with US$154,025 and a 
mean of US$85,240.88 for pemetrexed/cisplatin and the TKIs respectively. Cost dis-
tribution among acquisition, application, medical care and disease progression cost 
for the TKIs average was 19%, 0%, 12% and 69% respectively. Pemetrexed/cisplatin 
cost distribution was 5%, 2%, 5% and 88% at the same core items. cOnclusiOns: 
The economic burden in the treatment of NSCLC with EGFR mutation is heavily 
weighted in the disease progression cost. Even though pemetrexed/cisplatin has 
the lowest drug acquisition cost, it has the most expensive cost of treatment as a 
whole. A drug acquisition investment in TKIs is worth paying as its cost of treatment 
was estimated to be lower in a five year horizon.
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Objectives: To compare the cost of treatment of selected cancers with patented 
drugs: India versus neighboring countries. MethOds: Patented anticancer drugs 
(expiring in/after 2016) were selected using USFDA Orange-Book. These drugs were 
further, screened at the Indian national regulatory database for their marketing 
approval status in the country. The price of these drugs was calculated using CIMS 
– India online. Indication and dose as approved by USFDA for CML and Advance 
Breast Cancer were considered to estimate the cost of therapy. The STGs recom-
mended by cancer.org were used. Results: Twelve patented anticancer drugs are 
approved for marketing in India. Of these, we note that 4 are not available in the 
Indian market (Crizotinib, Ruxolitinib, Degarelix & Vemurafenib); and, the patent of 
3 has been challenged (Sorafenib, Dasatinib & Fulvestrant). Lapatinib is approved for 
treatment of CML while Nilotinib, Ixabepilone & Eribulin are for different stages of 
Breast Cancer. The cost of treatment of CML using Lapatinib is $8000/year in India; 
and, this is $18000, $17000, $17000 & $7000 for Philippines, Malaysia, Pakistan & 
Indonesia, respectively. Likewise, the cost of treatment of Advanced Breast Cancer 
using Nilotinib is $3000/year in India while $67000, $54000, $38000 & $4000 for 
Malaysia, Pakistan, Indonesia & Philippines, respectively. The costs are rounded. 
Though it is not meaningful to compare these costs with American costs; CML treat-
ment costs $51000/year while for Advance Breast Cancer treatment costs $1,20,000/
year. cOnclusiOns: In India, the cost of treatment of CML is approximately half 
when compared to most of the neighboring countries. For Advanced Breast Cancer, 
the costs are 12-22 times lower on similar comparison.
